Citation
Nogueira, Monize Aydar, et al. "Omega-3 Polyunsaturated Fatty Acids in Treating Non-alcoholic Steatohepatitis: a Randomized, Double-blind, Placebo-controlled Trial." Clinical Nutrition (Edinburgh, Scotland), vol. 35, no. 3, 2016, pp. 578-86.
Nogueira MA, Oliveira CP, Ferreira Alves VA, et al. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2016;35(3):578-86.
Nogueira, M. A., Oliveira, C. P., Ferreira Alves, V. A., Stefano, J. T., Rodrigues, L. S., Torrinhas, R. S., Cogliati, B., Barbeiro, H., Carrilho, F. J., & Waitzberg, D. L. (2016). Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition (Edinburgh, Scotland), 35(3), 578-86. https://doi.org/10.1016/j.clnu.2015.05.001
Nogueira MA, et al. Omega-3 Polyunsaturated Fatty Acids in Treating Non-alcoholic Steatohepatitis: a Randomized, Double-blind, Placebo-controlled Trial. Clin Nutr. 2016;35(3):578-86. PubMed PMID: 26047766.
TY - JOUR
T1 - Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
AU - Nogueira,Monize Aydar,
AU - Oliveira,Claudia Pinto,
AU - Ferreira Alves,Venâncio Avancini,
AU - Stefano,José Tadeu,
AU - Rodrigues,Lívia Samara Dos Reis,
AU - Torrinhas,Raquel Susana,
AU - Cogliati,Bruno,
AU - Barbeiro,Hermes,
AU - Carrilho,Flair José,
AU - Waitzberg,Dan Linetzky,
Y1 - 2015/05/21/
PY - 2014/09/23/received
PY - 2015/03/27/revised
PY - 2015/05/08/accepted
PY - 2015/6/7/entrez
PY - 2015/6/7/pubmed
PY - 2018/1/18/medline
KW - Alpha-linolenic acid
KW - Docosahexaenoic acid
KW - Eicosapentaenoic acid
KW - Fish oil
KW - Flaxseed oil
KW - Nonalcoholic steatohepatitis
SP - 578
EP - 86
JF - Clinical nutrition (Edinburgh, Scotland)
JO - Clin Nutr
VL - 35
IS - 3
N2 - BACKGROUND: & aims: Few clinical trials have addressed the potential benefits of omega-3 polyunsaturated fatty acids (PUFAs) on non-alcoholic steatohepatitis (NASH). We evaluated the effects of supplementation with omega-3 PUFAs from flaxseed and fish oils in patients with biopsy-proven NASH. METHODS: Patients received three capsules daily, each containing 0.315 g of omega-3 PUFAs (64% alpha-linolenic [ALA], 16% eicosapentaenoic [EPA], and 21% docosahexaenoic [DHA] acids; n-3 group, n = 27) or mineral oil (placebo group, n = 23). Liver biopsies were evaluated histopathologically by the NASH activity score (NAS). Plasma levels of omega-3 PUFAs were assessed as a marker of intake at baseline and after 6 months of treatment. Secondary endpoints included changes in plasma biochemical markers of lipid metabolism, inflammation, and liver function at baseline and after 3 and 6 months of treatment. RESULTS: At baseline, NAS was comparable between the groups (p = 0.98). After intervention with omega-3 PUFAs, plasma ALA and EPA levels increased (p ≤ 0.05). However in the placebo group, we also observed increased EPA and DHA (p ≤ 0.05), suggesting an off-protocol intake of PUFAs. NAS improvement/stabilization was correlated with increased ALA in the n-3 group (p = 0.02) and with increased EPA (p = 0.04) and DHA (p = 0.05) in the placebo group. Triglycerides were reduced after 3 months in the n-3 group compared to baseline (p = 0.01). CONCLUSIONS: In NASH patients, the supplementation of omega-3 PUFA from flaxseed and fish oils significantly impacts on plasma lipid profile of patients with NASH. Plasma increase of these PUFAs was associated with better liver histology. (ID 01992809).
SN - 1532-1983
UR - https://www.unboundmedicine.com/medline/citation/26047766/Omega_3_polyunsaturated_fatty_acids_in_treating_non_alcoholic_steatohepatitis:_A_randomized_double_blind_placebo_controlled_trial_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0261-5614(15)00131-4
DB - PRIME
DP - Unbound Medicine
ER -